EGFR (Ab-1197) Antibody

1. Amphiregulin, contained in non-small-cell lung carcinoma-derived exosomes, induces osteoclast differentiation through activation of the EGFR pathway. PMID: 28600504
2. Combining vorinostat with an EGFR tyrosine kinase inhibitor (TKI) can reverse EGFR TKI resistance in non-small cell lung cancer (NSCLC). PMID: 30365122
3. The feasibility of utilizing the radiocobalt-labeled anti-EGFR affibody conjugate ZEGFR:2377 as an imaging agent has been investigated. PMID: 30320363
4. Among various transfection complexes, 454 lipopolyplexes modified with the bidentate PEG-GE11 agent demonstrate the best EGFR-dependent uptake, as well as luciferase and NIS gene expression, into PMID: 28877405
5. EGFR amplification was significantly higher in the oral squamous cell carcinoma (OSCC) group compared to the control group (P=0.018) and was associated with advanced clinical stage (P=0.013), regardless of age. Patients with EGFR overexpression had worse survival rates, as did patients with T3-T4 tumors and positive margins. EGFR overexpression negatively impacts disease progression. PMID: 29395668
6. Clonal analysis revealed that the dominant JAK2 V617F-positive clone in Polycythemia Vera harbors an EGFR C329R substitution, suggesting that this mutation may contribute to clonal expansion. PMID: 28550306
7. Baseline circulating tumor cell count could serve as a predictive biomarker for EGFR-mutated and ALK-rearranged non-small cell lung cancer, providing valuable guidance and monitoring for patients undergoing molecular targeted therapies. PMID: 29582563
8. High EGFR expression has been associated with cystic fibrosis. PMID: 29351448
9. Findings suggest a mechanism by which EGFR inhibition suppresses respiratory syncytial virus by activating endogenous epithelial antiviral defenses. PMID: 29411775
10. This study detected the emergence of the T790M mutation within the EGFR cDNA in a subset of erlotinib-resistant PC9 cell models using Sanger sequencing and droplet digital PCR-based methods. These results demonstrate that the T790M mutation can arise de novo following treatment with erlotinib. PMID: 29909007
11. This study showed that miR145 regulates the EGFR/PI3K/AKT signaling pathway in patients with non-small cell lung cancer. PMID: 30226581
12. Among NSCLC patients treated with EGFR-TKI, those with T790M mutations were frequently found to also exhibit 19 deletions, compared to T790M-negative patients. Additionally, T790M-positive patients exhibited a longer progression-free survival (PFS). Therefore, screening these patients for T790M mutations may contribute to improved survival outcomes. PMID: 30150444
13. High EGFR expression is associated with breast carcinoma. PMID: 30139236
14. Findings indicate that CAV-1 promotes anchorage-independent growth and anoikis resistance in detached SGC-7901 cells. This effect is linked to the activation of Src-dependent epidermal growth factor receptor-integrin beta signaling, as well as the phosphorylation of PI3K/Akt and MEK/ERK signaling pathways. PMID: 30088837
15. Results suggest that FOXK2 inhibits the malignant phenotype of clear-cell renal cell carcinoma and acts as a tumor suppressor, possibly through the inhibition of EGFR. PMID: 29368368
16. EGFR mutation status in advanced non-small cell lung cancer (NSCLC) patients has been observed to change significantly. PMID: 30454543
17. Distinct signaling pathways play a role in regulating PD-L1 expression in EGFR-mutated lung adenocarcinoma. PMID: 30454551
18. Internal tandem duplication of the kinase domain defines a genetic subgroup of congenital mesoblastic nephroma, transcending histological subtypes. PMID: 29915264
19. The expression level of EGFR increased with higher stages and pathologic grades of bladder transitional cell carcinoma (BTCC), and the significantly increased expression of HER-2 was statistically associated with clinical stages and tumor recurrence. Additionally, the expression level of HER-2 increased with higher clinical stages of BTCC. EGFR expression and HER-2 levels were positively correlated in BTCC samples. PMID: 30296252
20. Results demonstrate that GGA2 interacts with the EGFR cytoplasmic domain to stabilize its expression and reduce its lysosomal degradation. PMID: 29358589
21. Combination therapy of apatinib with icotinib for primary acquired resistance to icotinib may be a viable option for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. However, clinicians must be aware of the potential side effects associated with this therapy. PMID: 29575765
22. This report describes a rare case presenting as multiple lung adenocarcinomas with four distinct EGFR gene mutations detected in three lung tumors. PMID: 29577613
23. Findings support the involvement of EGFR, HER2, and HER3 in the aggressiveness of basal cell carcinoma (BCC) and in tumor differentiation towards different histological subtypes. PMID: 30173251
24. The ratio of sFlt-1/sEGFR could serve as a novel candidate biochemical marker for monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR may be involved in the pathogenesis of small for gestational age in preterm preelampsia. PMID: 30177039
25. This study confirmed the prognostic effect of EGFR and VEGFR2 for recurrent disease and survival rates in patients with epithelial ovarian cancer. PMID: 30066848
26. Data suggest that diagnostic or therapeutic chest radiation may predispose patients with decreased stromal PTEN expression to secondary breast cancer. Prophylactic EGFR inhibition may mitigate this risk. PMID: 30018330
27. Findings suggest a unique regulatory feature of PHLDA1 in inhibiting the ErbB receptor oligomerization process, thereby controlling the activity of the receptor signaling network. PMID: 29233889
28. This study observed the occurrence of not only the EGFR C797S mutation but also L792F/Y/H in three NSCLC clinical subjects who developed acquired resistance to osimertinib treatment. PMID: 28093244
29. Data indicate that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was significantly higher than that of non-invasive GHPA. PMID: 29951953
30. Concurrent mutations in genes such as CDKN2B or RB1 were associated with worse clinical outcomes in lung adenocarcinoma patients harboring EGFR active mutations. PMID: 29343775
31. The ER-alpha36/EGFR signaling loop promotes the growth of hepatocellular carcinoma cells. PMID: 29481815
32. High EGFR expression is associated with colorectal cancer. PMID: 30106444
33. High EGFR expression is associated with gefitinib resistance in lung cancer. PMID: 30106446
34. High EGFR expression is associated with tumor-node-metastasis in non-small cell lung cancer. PMID: 30106450
35. Data suggest that Thr264 in TRPV3 is a key ERK1 phosphorylation site mediating EGFR-induced sensitization of TRPV3 to stimulate signaling pathways involved in regulating skin homeostasis. (TRPV3 = transient receptor potential cation channel subfamily V member-3; ERK1 = extracellular signal-regulated kinase-1; EGFR = epidermal growth factor receptor) PMID: 29084846
36. The frequency of EGFR mutations in Middle Eastern and African patients is higher than that observed in white populations, but still lower than the frequency reported in Asian populations. PMID: 30217176
37. EGFR-containing exosomes derived from cancer cells could favor the development of a liver-like microenvironment, promoting liver-specific metastasis. PMID: 28393839
38. Results reveal that the EGF-STAT3 signaling pathway promotes and maintains colorectal cancer (CRC) stemness. Additionally, crosstalk between STAT3 and Wnt activates the Wnt/beta-catenin signaling pathway, which is also responsible for cancer stemness. Therefore, STAT3 is a potential therapeutic target for CRC treatment. PMID: 30068339
39. Findings indicated that the T790M mutation is not only associated with EGFR-TKI resistance but may also play a functional role in the malignant progression of lung adenocarcinoma. PMID: 29887244
40. LOX regulates EGFR cell surface retention to drive tumor progression. PMID: 28416796
41. In a Han Chinese population, EGFR gene polymorphisms, rs730437 and rs1468727, and haplotype A-C-C were identified as potential protective factors against the development of Alzheimer's disease. PMID: 30026459
42. EGFR proteins localized at different cellular locations in lung adenocarcinoma might influence the biology of cancer cells and serve as an independent indicator of a more favorable prognosis and treatment response. PMID: 29950164
43. The crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, a novel type of EGFR TKI, has been determined. This inhibitor binds to EGFR reversibly and does not rely on Cys 797. PMID: 29802850
44. Overexpression of miR-452-3p promoted cell proliferation and mobility while suppressing apoptosis. MiR-452-3p enhanced EGFR and phosphorylated AKT (pAKT) expression, but inhibited p21 expression levels. MiR-452-3p promoted hepatocellular carcinoma (HCC) cell proliferation and mobility by directly targeting the CPEB3/EGFR axis. PMID: 29332449
45. This study demonstrated that the D2A sequence of the uPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
46. BRAF and EGFR inhibitors have the ability to synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. PMID: 29534162
47. This study confirms a direct correlation between MSI1 and EGFR, supporting the significant role of MSI1 in activating EGFR through NOTCH/WNT pathways in esophageal squamous cell carcinoma. PMID: 30202417
48. Three lines of tyrosine kinase inhibitor (TKI) therapy can prolong survival in non-small cell lung cancer (NSCLC) patients. Elderly patients can benefit from TKI therapy. Patients with EGFR mutation-positive tumors can benefit from second-line or third-line TKI therapy. PMID: 29266865
49. EGFR 19Del and L858R mutations serve as reliable biomarkers for predicting the clinical response to EGFR-TKIs. 19Del mutations may be associated with better clinical outcomes. PMID: 29222872
50. HMGA2-EGFR constitutively induced higher levels of phosphorylated STAT5B compared to EGFRvIII. PMID: 29193056

Show More

Hide All

HGNC: 3236

OMIM: 131550

KEGG: hsa:1956

STRING: 9606.ENSP00000275493

UniGene: Hs.488293